ArticleClinical rheumatology2026
Protective effects of Syringic acid on joint inflammation and damage in a rat model of rheumatoid arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammation and joint damage are hallmarks of rheumatoid arthritis (RA), a chronic autoimmune disease.
objectivesThis study investigated the anti-arthritic efficacy and mechanisms of Syringic acid (SA), a natural phenolic compound, in a Complete Freund's Adjuvant (CFA)-induced arthritis rat model.
methodsArthritis was induced in Wistar rats, which were then orally treated with SA (50, 100, 200 mg/kg) or prednisolone for 28 days. Paw swelling, arthritic index, body weight, motor functions, cytokine levels (Nuclear factor kappa B (NF-κB), Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β)), antioxidant enzyme activities, histopathology, and radiological changes were assessed. Molecular docking studies were also performed.
resultsSA significantly reduced paw swelling and arthritic index, improved body weight and motor functions, and modulated inflammatory cytokines (NF-κB, TNF-α, IL-6, IL-1β) and oxidative stress markers dose-dependently. Histopathological and radiological analyses confirmed SA's protective effects on joint integrity. Docking studies showed strong binding affinities of SA to NF-κB and TNF-α. SA exhibits significant anti-inflammatory and anti-arthritic properties in CFA-induced RA, modulating cytokine pathways and reducing oxidative stress.
conclusionThese findings suggest SA's potential as a therapeutic agent for RA, warranting further clinical investigation. Key Points • Syringic acid (SA) modulated key pro-inflammatory cytokines (NF-κB, TNF-α, IL-6, IL-1β) and enhanced antioxidant enzyme activities. • Molecular docking demonstrated strong binding of SA with NF-κB and TNF-α, supporting its immunomodulatory role. • The findings highlight SA's potential as a natural immunomodulator for RA, warranting further clinical exploration.
Indexed as
Identifiers
41790355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.